# Empasiprubart PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/empasiprubart

> The next catalyst for empasiprubart, sponsored by ARGENX SE (ARGX), is its topline data readout, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | empasiprubart |
| Codes | ARGX-117 |
| Sponsor | ARGENX SE (ARGX) https://sec-api.dev/companies/argx/catalysts |
| Indications | [Multifocal Motor Neuropathy (MMN)](https://sec-api.dev/indications/multifocal-motor-neuropathy-mmn), [Chronic Inflammatory Demyelinating Polyneuropathy](https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyneuropathy) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### 1H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "We also announced CIDP as the 4th indication for empasiprubart during our R&D Day on July 16, 2024 and plan to start a registrational study in CIDP evaluating empasiprubart head-to-head versus intravenous IgG (IVIg) in first half of 2025." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-25-000024): "We also announced CIDP as the 4th indication for empasiprubart during our R&D Day on July 16, 2024 and plan to start a registrational study in CIDP evaluating empasiprubart head-to-head versus intravenous IgG (IVIg) in first half of 2025." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "In particular, we have advanced the clinical development of empasiprubart in MMN, currently in Phase 3, DGF in the context of kidney transplants and DM, currently in Phase 2, and expect to start a registrational clinical trial for our fourth selected indication, CIDP in 2025." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-25-000024): "In particular, we have advanced the clinical development of empasiprubart in MMN, currently in Phase 3, DGF in the context of kidney transplants and DM, currently in Phase 2, and expect to start a registrational clinical trial for our fourth selected indication, CIDP in 2025." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-02-27, last confirmed 2025-07-31.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "•Topline results expected for DGF in the second half of 2025 and for DM in first half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/a04earningspressreleasehy.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000028): "•Topline results expected for DGF in second half of 2025 and for DM in first half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "•Proof-of-concept studies ongoing in DGF and DM; topline results expected for DGF in second half of 2025 and for DM in first half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "Topline results expected 1H 2026. argenx Annual Report 2024 2024 In Brief 16 empasiprubart ARGX-119" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Multifocal Motor Neuropathy (MMN); MMN.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06742190 (A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06742190

### Dec 2026: topline data readout

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multifocal Motor Neuropathy (MMN); MMN.
- First seen 2025-01-13, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000034): "•Topline results from the Phase 3 EMPASSION study (MMN) expected in December 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "•Topline results from registrational EMPASSION study (MMN) evaluating empasiprubart head-to-head versus IVIg expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/a04earningspressreleasehy.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000028): "•Topline results from registrational EMPASSION study (MMN) evaluating empasiprubart head-to-head versus IVIg expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000028): "(7) its plans to develop empasiprubart, including (a) registrational EMPASSION study in MMN, with topline results expected in second half of 2026, (b) registrational EMVIGORATE study in CIDP, expected to start in first half of 2025 and (c) topline results for DGM and DM expected in second half of 2025 and first half of 2026, respectively" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "•Registrational EMPASSION study ongoing in MMN evaluating empasiprubart head-to-head versus IVIg; topline results expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "its plans to develop empasiprubart, including: (1) registrational EMPASSION study in MMN, with topline results expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-002791): "Registrational EMPASSION study ongoing in MMN evaluating empasiprubart head-to-head versus IVIg; topline results expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000110465925002791/tm253121d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000033): "Registrational MMN study readout for empasiprubart on track for 4Q26, supporting a second pipeline-in-a-product opportunity" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000033/a04earningspressreleasehy.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000033): "•Topline results from registrational EMPASSION study (MMN) expected in fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000033/a04earningspressreleasehy.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000059): "•Topline results from registrational EMPASSION study (MMN) expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000059/a02earningspressreleaseq3.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "2027, respectively, (6) its plans to develop empasiprubart, including (a) registrational EMPASSION study in MMN, with topline results expected in second half of 2026, (b) registrational EMVIGORATE study in CIDP, expected to start in first half of 2025 and (c) topline results for DGM and DM expected in second half of 2025 and first half of 2026, respectively, (7) its plans to develop ARGX-119, including: (a) the registrational study to start in CMS in 2026; (b)" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/argx-20250630_d2.htm
- ClinicalTrials.gov: "NCT06742190 (A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06742190

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06920004 (A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06920004

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-03-19, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06920004 (A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT06920004
- SEC Form 10-K (accession 0001697862-26-000032): "•Topline results from EMVIGORATE clinical trial for empasiprubart (CIDP) expected in second half of 2027" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031739): "(2) topline results from EMVIGORATE and EMNERGIZE studies (CIDP) expected in second half of 2027" https://www.sec.gov/Archives/edgar/data/1697862/000162828026031739/a02earningspressreleaseq1.htm
- SEC Form 10-K (accession 0001697862-26-000032): "Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "Topline results from EMVIGORATE clinical trial for empasiprubart (CIDP) expected in second half of 2027 Our Vision 2030 sets the goal to have five new molecules in Phase 3, ten labeled indications, and 50,000 patients on treatment by 2030." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm

## Same indication

- [ARGX-117](https://sec-api.dev/pdufa/argx-117) (ARGX)
- [Batoclimab](https://sec-api.dev/pdufa/batoclimab) (IMVT)
- [Batoclimab 680 milligrams (mg) subcutaneous (sc) weekly](https://sec-api.dev/pdufa/batoclimab-680-milligrams-mg-subcutaneous-sc-weekly) (IMVT)
- [Claseprubart](https://sec-api.dev/pdufa/claseprubart) (DNTH)
- [Empasiprubart iv](https://sec-api.dev/pdufa/empasiprubart-iv) (ARGX)
- [Imeroprubart](https://sec-api.dev/pdufa/imeroprubart) (IMVT)
- [Riliprubart](https://sec-api.dev/pdufa/riliprubart) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/empasiprubart.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Empasiprubart PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/empasiprubart

```bibtex
@misc{secapidev_pdufa_empasiprubart_20261116,
  title        = {Empasiprubart PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/empasiprubart}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_empasiprubart_20261116","title":"Empasiprubart PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/empasiprubart","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
